Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis

Tannaz Jamialahmadi; Elaheh Mirhadi; Željko Reiner; Kasim Sakran Abass; Wael Almahmeed; Salim S. Virani; Amirhossein Sahebkar

doi:10.1007/s11883-025-01346-3

Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis

Tannaz Jamialahmadi
, Elaheh Mirhadi
, Željko Reiner
, Kasim Sakran Abass
, Wael Almahmeed
, Salim S. Virani
, Amirhossein Sahebkar

Office of the Provost

Research output: Contribution to journal › Review article › peer-review

4 Citations (Scopus)

Abstract

Purpose of Review: To evaluate the effect of pioglitazone, a member of the thiazolidinedione family of drugs known for its antihyperglycemic properties, on lipoprotein (a) [Lp(a)]. Pioglitazone is recognized for enhancing insulin sensitivity and β-cell function, and it also has a positive influence on the overall lipid profile. Recent Findings: Meta-analysis of 7 studies (4 RCTs and three non-RCTs) including 254 patients showed a significant decrease of circulating Lp(a) levels after treatment with pioglitazone (SMD: -0.373, 95% CI: -0.642, -0.104, p = 0.007). The reduction in circulating Lp(a) was robust in the leave-one-out sensitivity analysis. The presented results were obtained following a comprehensive literature search conducted in PubMed, Scopus, Embase, and Web of Science, covering studies from their inception up to March 1, 2025. Summary: Pioglitazone significantly decreases circulating Lp(a) concentrations. This decrease might have a beneficial effect on atherosclerotic cardiovascular disease (ASCVD) in high-risk patients.

Original language	English (US)
Article number	94
Journal	Current Atherosclerosis Reports
Volume	27
Issue number	1
DOIs	https://doi.org/10.1007/s11883-025-01346-3
Publication status	Published - Dec 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Atherosclerosis
Cardiovascular disease
Lipoprotein(a)
Meta-analysis
Pioglitazone

Access to Document

10.1007/s11883-025-01346-3

Cite this

@article{82dbbf228884417e8fc3b3b7a645c81d,

title = "Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis",

abstract = "Purpose of Review: To evaluate the effect of pioglitazone, a member of the thiazolidinedione family of drugs known for its antihyperglycemic properties, on lipoprotein (a) [Lp(a)]. Pioglitazone is recognized for enhancing insulin sensitivity and β-cell function, and it also has a positive influence on the overall lipid profile. Recent Findings: Meta-analysis of 7 studies (4 RCTs and three non-RCTs) including 254 patients showed a significant decrease of circulating Lp(a) levels after treatment with pioglitazone (SMD: -0.373, 95\% CI: -0.642, -0.104, p = 0.007). The reduction in circulating Lp(a) was robust in the leave-one-out sensitivity analysis. The presented results were obtained following a comprehensive literature search conducted in PubMed, Scopus, Embase, and Web of Science, covering studies from their inception up to March 1, 2025. Summary: Pioglitazone significantly decreases circulating Lp(a) concentrations. This decrease might have a beneficial effect on atherosclerotic cardiovascular disease (ASCVD) in high-risk patients.",

keywords = "Atherosclerosis, Cardiovascular disease, Lipoprotein(a), Meta-analysis, Pioglitazone",

author = "Tannaz Jamialahmadi and Elaheh Mirhadi and {\v Z}eljko Reiner and Abass, \{Kasim Sakran\} and Wael Almahmeed and \{S. Virani\}, Salim and Amirhossein Sahebkar",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.",

year = "2025",

month = dec,

doi = "10.1007/s11883-025-01346-3",

language = "English (US)",

volume = "27",

journal = "Current Atherosclerosis Reports",

issn = "1523-3804",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Effects of Pioglitazone On Lipoprotein(a)

T2 - A Meta-analysis

AU - Jamialahmadi, Tannaz

AU - Mirhadi, Elaheh

AU - Reiner, Željko

AU - Abass, Kasim Sakran

AU - Almahmeed, Wael

AU - S. Virani, Salim

AU - Sahebkar, Amirhossein

N1 - Publisher Copyright: © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.

PY - 2025/12

Y1 - 2025/12

N2 - Purpose of Review: To evaluate the effect of pioglitazone, a member of the thiazolidinedione family of drugs known for its antihyperglycemic properties, on lipoprotein (a) [Lp(a)]. Pioglitazone is recognized for enhancing insulin sensitivity and β-cell function, and it also has a positive influence on the overall lipid profile. Recent Findings: Meta-analysis of 7 studies (4 RCTs and three non-RCTs) including 254 patients showed a significant decrease of circulating Lp(a) levels after treatment with pioglitazone (SMD: -0.373, 95% CI: -0.642, -0.104, p = 0.007). The reduction in circulating Lp(a) was robust in the leave-one-out sensitivity analysis. The presented results were obtained following a comprehensive literature search conducted in PubMed, Scopus, Embase, and Web of Science, covering studies from their inception up to March 1, 2025. Summary: Pioglitazone significantly decreases circulating Lp(a) concentrations. This decrease might have a beneficial effect on atherosclerotic cardiovascular disease (ASCVD) in high-risk patients.

AB - Purpose of Review: To evaluate the effect of pioglitazone, a member of the thiazolidinedione family of drugs known for its antihyperglycemic properties, on lipoprotein (a) [Lp(a)]. Pioglitazone is recognized for enhancing insulin sensitivity and β-cell function, and it also has a positive influence on the overall lipid profile. Recent Findings: Meta-analysis of 7 studies (4 RCTs and three non-RCTs) including 254 patients showed a significant decrease of circulating Lp(a) levels after treatment with pioglitazone (SMD: -0.373, 95% CI: -0.642, -0.104, p = 0.007). The reduction in circulating Lp(a) was robust in the leave-one-out sensitivity analysis. The presented results were obtained following a comprehensive literature search conducted in PubMed, Scopus, Embase, and Web of Science, covering studies from their inception up to March 1, 2025. Summary: Pioglitazone significantly decreases circulating Lp(a) concentrations. This decrease might have a beneficial effect on atherosclerotic cardiovascular disease (ASCVD) in high-risk patients.

KW - Atherosclerosis

KW - Cardiovascular disease

KW - Lipoprotein(a)

KW - Meta-analysis

KW - Pioglitazone

UR - https://www.scopus.com/pages/publications/105017185672

U2 - 10.1007/s11883-025-01346-3

DO - 10.1007/s11883-025-01346-3

M3 - Review article

C2 - 41003906

AN - SCOPUS:105017185672

SN - 1523-3804

VL - 27

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

IS - 1

M1 - 94

ER -

Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this